Bone marrow stromal cells maintain the adult skeleton by forming osteoblasts throughout life that regenerate bone and repair fractures. We discovered that subsets of these stromal cells, osteoblasts, osteocytes, and hypertrophic chondrocytes secrete a C-type lectin domain protein, Clec11a, which promotes osteogenesis. Clec11a-deficient mice appeared developmentally normal and had normal hematopoiesis but reduced limb and vertebral bone. Clec11a-deficient mice exhibited accelerated bone loss during aging, reduced bone strength, and delayed fracture healing. Bone marrow stromal cells from Clec11a-deficient mice showed impaired osteogenic differentiation, but normal adipogenic and chondrogenic differentiation. Recombinant Clec11a promoted osteogenesis by stromal cells in culture and increased bone mass in osteoporotic mice in vivo. Recombinant human Clec11a promoted osteogenesis by human bone marrow stromal cells in culture and in vivo. Clec11a thus maintains the adult skeleton by promoting the differentiation of mesenchymal progenitors into mature osteoblasts. In light of this, we propose to call this factor Osteolectin.https://doi.org/10.7554/eLife.18782.001
Fate mapping studies in vivo show there are multiple distinct waves of mesenchymal progenitors that form skeletal tissues during development and then maintain the skeleton throughout adulthood (Liu et al., 2013; Maes et al., 2010; Mizoguchi et al., 2014; Park et al., 2012; Takashima et al., 2007; Worthley et al., 2015; Zhou et al., 2014a). These include Osterix+ cells that give rise to osteoblasts, osteocytes, and stromal cells in developing bones (Liu et al., 2013; Maes et al., 2010; Mizoguchi et al., 2014), Nestin-CreER-expressing cells that transiently form osteoblasts and bone marrow stromal cells in the early postnatal period (Méndez-Ferrer et al., 2010; Ono et al., 2014a; Takashima et al., 2007), Grem1-expressing cells that form osteoblasts, chondrocytes, and stromal cells postnatally (Worthley et al., 2015) and Leptin Receptor (LepR)-expressing stromal cells that are the major source of bone and adipocytes in adult mouse bone marrow (Mizoguchi et al., 2014; Zhou et al., 2014a). Osterix+ osteogenic progenitors also persist periosteally, on the outer surface of adult bones, where they help to repair bone injuries (Maes et al., 2010).
Bone marrow stromal cells include skeletal stem cells (SSCs) as well as multiple other populations of mesenchymal progenitors (Chan et al., 2015). SSCs are multipotent progenitors that form fibroblast colonies in culture (CFU-F) with the potential to differentiate into osteoblasts, chondrocytes, and adipocytes (Bianco and Robey, 2015; Friedenstein et al., 1970). Bone marrow CFU-F can be identified based on the expression of CD146, CD271, VCAM-1, and Thy-1 in humans, or LepR, PDGFRα, CD51, and/or CD105 in mice, as well as the lack of expression of hematopoietic and endothelial markers (Chan et al., 2009, 2015; James et al., 2015; Mabuchi et al., 2013; Morikawa et al., 2009; Omatsu et al., 2010; Park et al., 2012; Sacchetti et al., 2007; Zhou et al., 2014a). CFU-F are enriched among bone marrow stromal cells that express high levels of the hematopoietic growth factors Scf (Zhou et al., 2014a) and Cxcl12 (Ding and Morrison, 2013; Omatsu et al., 2014; Sugiyama et al., 2006).
Multiple growth factor families promote osteogenesis including Wnts (Cui et al., 2011; Krishnan et al., 2006), Bone Morphogenetic Proteins (BMPs) (Nakamura et al., 2007; Rahman et al., 2015), and Insulin-like Growth Factors (Yakar and Rosen, 2003). However, these factors have broad effects on many tissues, precluding their systemic administration to promote osteogenesis. Sclerostin, a Wnt signaling inhibitor that is locally produced by osteocytes, negatively regulates bone formation (Li et al., 2005). Sclerostin inhibitors can be administered systemically to promote bone formation (McClung et al., 2014). Factors secreted by bone marrow stromal cells promote osteogenesis (Chan et al., 2015), though the full repertoire of such factors remains to be identified.
Osteoporosis is a progressive bone disease characterized by decreased bone mass and increased fracture risk (Harada and Rodan, 2003). Aging, estrogen insufficiency, long-term glucocorticoid use, and mechanical unloading all contribute to the development of osteoporosis (Harada and Rodan, 2003). Most existing osteoporosis therapies involve antiresorptive agents, such as bisphosphonates (Black et al., 1996; Liberman et al., 1995) and estrogens (Michaelsson et al., 1998), which reduce the rate of bone loss but do not promote new bone formation. Teriparatide, a small peptide derived from human parathyroid hormone (PTH; amino acids 1–34) is used clinically to promote the formation of new bone (Neer et al., 2001). Nonetheless, some patients cannot take Teriparatide (Kraenzlin and Meier, 2011) and its use is limited to two years because of a potential risk of osteosarcoma (Neer et al., 2001).
Clec11a (C-type lectin domain family 11, member A) is a secreted sulfated glycoprotein that is expressed in the bone marrow and can promote colony formation by human hematopoietic progenitors in culture (Bannwarth et al., 1998, 1999; Hiraoka et al., 1997; Mio et al., 1998). The plasma level of human Clec11a correlates with hemoglobin level (Keller et al., 2009; Ouma et al., 2010) and increases in patients after bone marrow transplantation (Ito et al., 2003). As a result, Clec11a has been considered a hematopoietic growth factor. However, Clec11 is also expressed in skeletal tissues (Hiraoka et al., 2001) and the physiological function of Clec11a in vivo has not yet been tested.
Reanalysis of our published microarray data (Ding et al., 2012) revealed that among enzymatically dissociated bone marrow cells, Clec11a was significantly more highly expressed by Scf-GFP+CD45-Ter119-CD31- stromal cells (more than 90% of which are also LepR+ [Zhou et al., 2014a]) and Col2.3-GFP+CD45-Ter119-CD31- osteoblasts as compared to VE-cadherin+ endothelial cells and unfractionated cells (Figure 1A). By RNA sequencing, Clec11a transcripts were at least 100-fold more abundant in PDGFRα+CD45-Ter119-CD31- bone marrow stromal cells (more than 90% of which are LepR+ [Zhou et al., 2014a]) as compared to unfractionated bone marrow cells (Figure 1B). A systematic analysis of Clec11a expression in bone marrow cells by quantitative reverse transcription PCR (qRT-PCR) showed that Clec11a was highly expressed by LepR+CD45-Ter119-CD31- stromal cells and Col2.3-GFP+CD45-Ter119-CD31- osteoblasts but not by hematopoietic cells (Figure 1C). Clec11a was also expressed at a very low level by B cell progenitors in the bone marrow and T cells in the spleen (Figure 1C).
Published gene expression profile data were consistent with our results. RNA-seq analysis showed 80-fold higher levels of Clec11a in bone fragments that contain osteoblasts and osteocytes as compared to whole bone marrow or skeletal muscle cells (Ayturk et al., 2013). Clec11a expression is 9-fold higher in Grem1+ SSCs as compared to Grem1- stromal cells (see GSE57729 from [Worthley et al., 2015]). LepR+ stromal cells are enriched for Grem1 expression (see GSE33158 from [Ding et al., 2012]).
To assess the Clec11a protein expression, we stained femur sections from eight week-old Prrx1-Cre; tdTomato reporter mice with a commercial polyclonal antibody against Clec11a. Prrx1-Cre recombines in limb bone marrow mesenchymal cells including SSCs, other bone marrow stromal cells, osteoblasts, osteocytes, and chondrocytes (Ding and Morrison, 2013; Greenbaum et al., 2013; Logan et al., 2002; Yue et al., 2016). In two month-old mice, most of the Clec11a staining was observed in and around the trabecular bone in the femur metaphysis (Figure 1F) as well as in cortical bone of the proximal femur (Figure 1H). This staining pattern was specific for Clec11a as we did not observe any staining in bone marrow sections from Clec11a deficient mice (Figure 1—figure supplement 1A and B; see below) or in sections stained with an isotype control in place of the anti-Clec11a antibody (Figure 1E,G, and I).
Within the distal femur metaphysis of Prrx1-Cre; tdTomato mice we observed Clec11a staining adjacent to Tomato+ stromal cells in the bone marrow near trabecular bone (Figure 1Fi), Tomato+ osteoblasts lining trabecular bone surfaces (Figure 1Fii), and Aggrecan+ hypertrophic chondrocytes (Figure 1Fiii; Figure 1—figure supplement 1D). In the cortical bone matrix, we also observed Clec11a staining amongst osteocytes (Figure 1H). We did not detect Clec11a expression by bone marrow stromal cells, osteoblasts, or osteocytes in much of the diaphysis. Nonetheless, given the tendency of secreted growth factors to concentrate in regions of extracellular matrix, especially within the bone matrix (Hauschka et al., 1986, 1988; Mohan and Baylink, 1991), Clec11a may be more broadly expressed by bone marrow stromal cells than is evident from the antibody staining pattern.
The position and morphology of the metaphyseal bone marrow stromal cells that were associated with Clec11a staining (Figure 1Fi) suggested that these cells included LepR+ cells. To test this, we stained femur sections from eight week-old Lepr-Cre; tdTomato mice with anti-Clec11a antibody. We observed Clec11a staining adjacent to a subset of Tomato+ stromal cells near trabecular bone in the metaphysis (Figure 1J) but not by Tomato+ stromal cells throughout most of the diaphysis. The Clec11a staining in LepR+ cells in the metaphysis (Figure 1J) was clearly above background (Figure 1I) but was dimmer than observed in and around bone matrix (Figure 1F and H). It is unclear whether this reflects the lower Clec11a expression by the LepR+ cells or whether Clec11a is bound and concentrated by bone matrix.
We observed a similar Clec11a expression pattern in vertebrae, with anti-Clec11a antibody staining in and around the vertebral trabecular bone near the growth plate as well as in cortical bone (Figure 1—figure supplement 1C). Our data thus indicate that Clec11a is expressed by subsets of LepR+ bone marrow stromal cells, osteoblasts, and hypertrophic chondrocytes in the metaphysis as well as by osteocytes in certain regions of cortical bone.
To test the physiological function of Clec11a we used CRISPR-Cas9 to generate a Clec11a mutant allele (Clec11a-/-) by deleting the second exon of Clec11a (Figure 1—figure supplement 1E). This was predicted to be a strong loss of function as exon 2 deletion introduced a frame shift that created a premature stop codon in exon 3 (Figure 1—figure supplement 1F). The predicted mutant protein did not contain any of the domains that are thought to be functionally important in Clec11a, including the polyglutamic acid sequence, the alpha-helical leucine zipper, or the C-type lectin domain (Figure 1—figure supplement 1F). Germline transmission of the mutant allele was confirmed by PCR and sequencing of genomic DNA (Figure 1—figure supplement 1G). Clec11a deficiency was also confirmed by qPCR analysis of bone marrow LepR+CD45-Ter119-CD31- cells from Clec11a-/- mice (Figure 1—figure supplement 1H) and by Clec11a cDNA sequencing to confirm exon two deletion (Figure 1—figure supplement 1I), and by the loss of Clec11a from the plasma Clec11a-/- mice (Figure 1—figure supplement 1J). Immunofluorescence analysis of femur sections with an anti-Clec11a polyclonal antibody suggested a complete loss of Clec11a protein from Clec11a-/- mice (Figure 1—figure supplement 1A and B).
Clec11a-/- mice were born with Mendelian frequency (Figure 1—figure supplement 1K) and appeared grossly normal (Figure 1K), with normal body mass at 2 and 10 months of age (Figure 1L). White blood cell, red blood cell, and platelet counts were normal in 2, 10, and 16 month-old Clec11a-/- mice (Figure 1—figure supplement 1L–N). Two and 10-month old Clec11a-/- mice also had normal bone marrow and spleen cellularity (Figure 1M), as well as normal frequencies of Mac1+Gr1+ myeloid cells, Ter119+CD71+ erythroid progenitors, CD3+ T cells, and B220+ B cells in the bone marrow and spleen (Figure 1N–Q). Clec11a-/- mice had normal frequencies of CD150+CD48-Lineage-Sca-1+c-kit+ HSCs (Kiel et al., 2005) and CD150-CD48-Lin-Sca-1+c-kit+multipotent progenitors (MPPs) (Kiel et al., 2008; Oguro et al., 2013) in the bone marrow and spleen (Figure 1R and S), as well as normal frequencies of CD34+FcγR+Lin-Sca-1-c-kit+granulocyte-macrophage progenitors (GMPs), CD34-FcγR-Lin-Sca-1-c-kit+megakaryocyte-erythrocyte progenitors (MEPs), CD34+FcγR-Lin-Sca-1-c-kit+ common myeloid progenitors (CMPs) (Akashi et al., 2000) and Flt3+IL7Rα+Lin-Sca-1lowc-kitlowcommon lymphoid progenitors (CLPs) (Kondo et al., 1997) in the bone marrow (Figure 1T). Bone marrow from two month-old Clec11a-/- mice gave long-term multilineage reconstitution upon transplantation into irradiated mice with normal levels of donor cell reconstitution (Figure 1—figure supplement 1O–R). Clec11a is therefore not required for normal hematopoiesis in adult mice.
Human recombinant Clec11a increases erythroid (BFU-E) and myeloid (CFU-G/M/GM) colony formation by human bone marrow cells when added to culture along with EPO or GM-CSF, respectively (Hiraoka et al., 1997, 2001). In cultures of mouse bone marrow cells, recombinant mouse Clec11a did not significantly increase BFU-E colony formation when added along with EPO and only slightly increased CFU-G/M/GM colony formation when added along with GM-CSF (Figure 1—figure supplement 1S and T).
To test whether Clec11a regulates osteogenesis we performed micro-CT analysis of the distal femur from sex-matched littermates. In no case did we observe any significant difference between Clec11a+/+ and Clec11a+/- mice (data not shown), so samples from these mice were combined as controls. We always compared sex-matched littermates within individual experiments, using paired statistical tests to assess the significance of differences across multiple independent experiments. Trabecular bone volume was significantly reduced (by 24 ± 18%) in two month-old Clec11a-/- mice as compared to littermate controls (Figure 2A and D). The Clec11a-/- mice had significantly reduced trabecular bone thickness, increased trabecular spacing, and decreased connectively density and bone mineral density (Figure 2D–I). With the exception of the reduction in bone mineral density, these defects seemed to worsen with age as 10 and 16 month-old Clec11a-/- mice exhibited more profound reductions in trabecular bone volume (62 ± 27% and 64 ± 11%, respectively), trabecular number, trabecular thickness and connectivity density, as well as increased trabecular spacing (Figure 2B–H).
MicroCT analysis of cortical bone parameters in the femur diaphysis from sex-matched littermates did not show significant differences between Clec11a-/- and control mice at 2 or 10 months of age (Figure 2—figure supplement 1A and B). However, 16 month-old Clec11a-/- mice exhibited significantly reduced cortical bone area, cortical area/total area ratio, and cortical thickness as compared to controls (Figure 2—figure supplement 1C–H). The femur length was slightly but significantly reduced in 2, 10 and 16 month-old Clec11a-/- mice as compared to littermate controls (Figure 2—figure supplement 1I). When we tested the mechanical strength of bones using a three point bending test we found significantly reduced peak load and fracture energy in the femur diaphysis of 2, 10, and 16 month-old Clec11a-/- as compared to sex-matched littermate control mice (Figure 2—figure supplement 1J–L).
Micro-CT analysis of L3 vertebrae as a whole, including both cortical and trabecular bone, showed a trend toward reduced bone volume in Clec11a-/- as compared to sex-matched littermate controls, though the difference was not statistically significant (Figure 2—figure supplement 1M–R). Trabecular bone volume was significantly reduced in the L3 vertebral body of Clec11a-/- as compared to controls at 2, 10, and 16 months of age (Figure 2J–M). We also observed significantly reduced trabecular number and significantly increased trabecular spacing in L3 vertebrae from 2, 10 and 16 month-old Clec11a-/- as compared to littermate controls (Figure 2N–P). Clec11a is therefore required to maintain limb and vertebral bone.
Alizarin red/alcian blue double staining at postnatal day 3 did not reveal any significant differences between Clec11a-/- and littermate control mice (Figure 2—figure supplement 1S). This suggests that Clec11a is not required for fetal skeletal development.
We performed calcein double labeling to assess the rate of trabecular bone formation (Figure 2S). The trabecular bone mineral apposition and trabecular bone formation rates were both significantly decreased in the femur metaphysis of 2 and 10 month-old Clec11a-/- as compared to sex-matched littermate control mice (Figure 2T and U; 16 month-old mice were not assessed in these experiments). In contrast, the urinary bone resorption marker deoxypyridinoline did not significantly differ between Clec11a-/- and littermate controls (Figure 2V). This suggests that the difference in trabecular bone volume between Clec11a-/- and littermate control mice reflected reduced bone formation, not a change in bone resorption.
To assess the mechanism by which Clec11a promotes osteogenesis in vivo we used multiple approaches to test whether it regulates the maintenance, proliferation, or differentiation of mesenchymal progenitors in the bone marrow. The frequency of LepR+CD45-Ter119-Tie2- stromal cells did not significantly differ between the bone marrow of Clec11a-/- and littermate control mice (Figure 3—figure supplement 1B). We also did not detect any difference in the rate of BrdU incorporation by these cells in vivo (Figure 3—figure supplement 1H) or the percentage of these cells that stained positively for activated caspase 3/7 (data not shown).
We also examined a series of mesenchymal stem and progenitor cell populations that had been identified in a prior study of postnatal day 3 bone marrow based on expression of CD51 and other markers (Chan et al., 2015). In 10 month-old bone marrow we were able to identify 5 of the 8 cell populations that had been identified in the neonatal bone marrow (Figure 3—figure supplement 1A). All of these cell populations were uniformly or nearly uniformly positive for LeprR expression as nearly all CD51+ bone marrow stromal cells were LepR+ and vice versa (Figure 3—figure supplement 1A). Consistent with the data on LepR+ cells above, we did not detect any effect of Clec11a deficiency on the frequency of these cell populations (Figure 3—figure supplement 1C–G), their rate of BrdU incorporation (Figure 3—figure supplement 1I–M), or the percentage of cells that stained positively for activated caspase 3/7 (data not shown). Clec11a is therefore not required in vivo for the maintenance, survival, or the proliferation of bone marrow mesenchymal progenitors.
To functionally assess this conclusion, we cultured at clonal density enzymatically dissociated femur bone marrow cells from Clec11a-/- and sex-matched littermate control mice at 2 and 10 months of age. We observed no difference in the frequency of cells that formed CFU-F colonies or in the number of cells per colony (Figure 2—figure supplement 1T and U). Clec11a is therefore not required for the maintenance of CFU-F in vivo or for their proliferation in culture.
To test whether Clec11a is required for the differentiation of mesenchymal progenitors, we cultured CFU-F from Clec11a-/- and littermate control bone marrow at clonal density, then replated equal numbers of Clec11a-/- or control cells into osteogenic, adipogenic, or chondrogenic culture conditions. Consistent with the decreased osteogenesis in vivo, bone marrow stromal cells from Clec11a-/- mice gave rise to significantly fewer cells with alkaline phosphatase (a marker of mature osteoblasts and pre-adipocytes) or alizarin red (a marker of mineralization by mature osteoblasts) staining as compared to control cells under osteogenic culture conditions (Figure 3A–D). qRT-PCR analysis of cells in these cultures showed that Clec11a deficiency did not significantly affect the expression of Sp7 (Osterix), Runx2, or Col1a1 but did significantly reduce the expression of Integrin binding sialoprotein (Ibsp) and Dentin matrix protein 1 (Dmp1) (Figure 3—figure supplement 1N). Sp7, Runx2, and Col1a1 are broadly expressed by immature osteogenic progenitors and osteoblasts (Jikko et al., 1999; Kulterer et al., 2007; Nakashima et al., 2002) whereas Ibsp and Dmp1 mark mature osteoblasts (Kalajzic et al., 2005). Clec11a was thus required for the differentiation of bone marrow mesenchymal progenitors into mature osteoblasts.
Under adipogenic (Figure 3E and F) and chondrogenic (Figure 3G and H) culture conditions we did not detect any difference between Clec11a-/- and control cells in terms of Oil Red O or Toluidine blue staining. Consistent with this, the number of Perilipin+ adipocytes (Figure 3I–K) and Safranin O+ chondrocytes (Figure 3L–N) in femur sections from two month-old mice did not differ between Clec11a-/- and sex matched littermate control mice. However, we did observe significantly more adipocytes in the femur sections from 10 month-old Clec11a-/- mice as compared to littermate controls (Figure 3—figure supplement 2A–C). The number of chondrocytes did not significantly differ between Clec11a-/- and littermate controls at 10 months of age (Figure 3—figure supplement 2D–F).
To test whether Clec11a is necessary for the differentiation of mesenchymal progenitors into mature osteoblasts in vivo, we cultured CFU-F from adult bone marrow at clonal density, then seeded equal numbers Clec11a-/- or control cells into collagen sponges and transplanted them subcutaneously into immunocompromised NSG mice (Figure 3—figure supplement 1O). Eight weeks after transplantation, ossicles generated from Clec11a-/- cells contained significantly less bone as compared to the ossicles generated from control cells (Figure 3—figure supplement 1P). In contrast, the number of adipocytes per unit area did not differ between ossicles containing Clec11a-/- as compared to control cells (Figure 3—figure supplement 1Q).
We performed mid-diaphyseal femur fractures in two month-old Clec11a-/- and sex-matched littermate controls. Two weeks later, Clec11a-/- mice had significantly less callus bone around the fracture site (Figure 4A) and significantly more callus cartilage (Figure 4B) as compared to controls, suggesting delayed endochondral ossification. MicroCT analysis of the callus at the fracture site two weeks after the fracture revealed significantly reduced trabecular bone volume, trabecular number, trabecular thickness, and trabecular connectivity density (Figure 4C–H) and significantly increased trabecular spacing (Figure 4I) in Clec11a-/- bones. The bone mineral density in the callus did not significantly differ between Clec11a-/- and control mice (Figure 4J). The callus volume, diameter, and polar moment of inertia were significantly increased in Clec11a-/- mice as compared to littermate controls (Figure 4K–M), further suggesting that fracture healing was compromised in Clec11a-/- mice (O'Neill et al., 2012).
To test whether Clec11a is sufficient to promote osteogenesis we constructed a HEK293 cell line that stably expressed mouse Clec11a with a C-terminal Flag tag. We affinity purified recombinant Clec11a (rClec11a) from the culture medium using anti-Flag M2 beads. Wild-type bone marrow cells were cultured to form CFU-F, then replated and grown under osteogenic culture conditions. Addition of rClec11a to these cultures significantly increased alizarin red staining, suggesting increased mineralization (Figure 5A and B). Addition of rClec11a also rescued osteogenesis by Clec11a-/- bone marrow stromal cells at 7 and 14 days after induction of differentiation (Figure 5—figure supplement 1J–M). Transient expression of mouse Clec11a cDNA in the MC3T3-E1 mouse pre-osteoblast cell line (Wang et al., 1999) increased osteogenic differentiation by these cells in culture (Figure 5—figure supplement 1H and I).
To test whether Clec11a is sufficient to promote the differentiation of bone marrow mesenchymal progenitors into mature osteoblasts, we sorted LepR+CD105+CD45-Ter119-CD31- cells from wild-type mice into recombinant Clecl11a (rClec11a)-containing and control cultures at clonal density. Addition of rClec11a to these cultures did not significantly affect the percentage of cells that formed CFU-F or the number of cells per colony (Figure 5—figure supplement 1A and B). Upon induction of differentiation, rClec11a significantly increased the number of alkaline phosphatase positive osteoblasts per colony (Figure 5—figure supplement 1D). This appeared to reflect a promotion of differentiation as rClec11a did not significantly affect the frequencies of dividing osteoblasts (Figure 5—figure supplement 1E) or osteoblasts undergoing apoptosis within the colonies (Figure 5—figure supplement 1F). Consistent with the experiments above, addition of rClec11a did not significantly affect Sp7, Runx2, or Col1a1 expression by cells within these cultures, but it did significantly increase the expression of Ibsp and Dmp1 (Figure 5—figure supplement 1G). Clec11a is thus sufficient to promote the differentiation of bone marrow mesenchymal progenitors into mature osteoblasts.
To test whether rClec11a promotes osteogenesis in vivo, we administered daily subcutaneous injections of rClec11a to two month-old wild-type mice for 28 days. Consistent with the in vitro data, rClec11a dose-dependently increased trabecular bone volume in the distal femur metaphysis (Figure 5C and D). The higher doses of rClec11a also significantly increased trabecular number and reduced trabecular spacing (Figure 5E–G). The increased osteogenesis was associated with a significantly increased mineralized bone surface (Figure 5H) and bone formation rate (Figure 5I), but did not affect bone resorption (Figure 5J). Cortical bone parameters in the femur diaphysis were not affected by rClec11a in these experiments (Figure 5—figure supplement 1N–S). rClec11a thus promotes osteogenesis in wild-type mice in vivo.
To test whether administration of rClec11a can rescue the bone loss phenotype in Clec11a-/- mice, we administered daily subcutaneous injections of 50 µg/kg rClec11a to six month-old Clec11a-/- mice for 28 days. This restored plasma Clec11a to control levels (data not shown). Consistent with this, Clec11a-/- mice exhibited significantly increased trabecular bone volume (Figure 5K and L), trabecular number, trabecular thickness, connectivity density, and decreased trabecular spacing (Figure 5M–Q). After rClec11a administration to Clec11a-/- mice, trabecular bone parameters were similar to those in normal control mice.
Ovariectomy in adult mice induces osteoporosis by increasing bone resorption (Rodan and Martin, 2000). We ovariectomized mice at two months of age then administered daily subcutaneous injections of recombinant human parathyroid hormone (PTH) fragment 1–34, rClec11a, or vehicle for 28 days before analysis by microCT. MicroCT analysis showed that trabecular bone volume and number were significantly reduced in ovariectomized mice (Figure 6A–C) while trabecular spacing was significantly increased (Figure 6E). Daily administration of PTH to ovariectomized mice significantly increased trabecular bone volume (Figure 6B) and trabecular number (Figure 6C), while reducing trabecular spacing (Figure 6E). Ovariectomy did not significantly affect the plasma Clec11a level (data not shown). Daily administration of rClec11a to ovariectomized mice significantly increased trabecular bone volume (Figure 6B) and trabecular number (Figure 6C), while reducing trabecular spacing (Figure 6E). Cortical bone parameters were not significantly changed by PTH or Clec11a administration in these experiments (Figure 6—figure supplement 1A–F). rClec11a can therefore prevent the loss of trabecular bone in ovariectomized mice.
Consistent with the fact that ovariectomy increases bone resorption (Harada and Rodan, 2003), the urinary bone resorption marker deoxypyridinoline was significantly increased in ovariectomized mice as compared to sham operated controls (Figure 6F). Administration of rClec11a or PTH did not significantly affect deoxypyridinoline levels (Figure 6F) or numbers of osteoclasts (Figure 6—figure supplement 1G) in ovariectomized mice. However, based on calcein double labeling and histomorphometry analysis, the trabecular bone formation rate (Figure 6G) and the number of osteoblasts associated with trabecular bones (Figure 6—figure supplement 1H) were significantly increased by rClec11a or PTH administration. rClec11a thus prevented the loss of trabecular bone in ovariectomized mice by promoting bone formation.
We also assessed the effect of rClec11a on a model of secondary osteoporosis in which bone loss was induced by dexamethasone injection, mimicking glucocorticoid-induced osteoporosis in humans (McLaughlin et al., 2002; Weinstein et al., 1998). Daily intraperitoneal administration of 20 mg/kg dexamethasone for four weeks in mice significantly reduced lymphocyte numbers in the blood without significantly affecting neutrophil or monocyte counts (Figure 6—figure supplement 2A–D). MicroCT analysis of the distal femur metaphysis showed significantly reduced trabecular bone volume and thickness in the dexamethasone-treated as compared to vehicle-treated mice (Figure 6H–L). Treatment of dexamethasone-treated mice with PTH significantly increased trabecular bone volume, trabecular number, and trabecular thickness while significantly reducing trabecular spacing (Figure 6H–L). Dexamethasone treatment did not significantly affect plasma Clec11a levels (Figure 6—figure supplement 2K), but administration of rClec11a to dexamethasone-treated mice significantly increased trabecular bone volume and trabecular number while significantly reducing trabecular spacing (Figure 6H–L). Dexamethasone treatment also significantly reduced cortical thickness but neither PTH nor rClec11a rescued this effect in these experiments (Figure 6—figure supplement 2E–J).
Consistent with the fact that dexamethasone reduces bone formation (Harada and Rodan, 2003), the rate of trabecular bone formation based on calcein double labeling (Figure 6M) and the numbers of osteoblasts in trabecular bone (Figure 6—figure supplement 2L) were significantly reduced in dexamethasone-treated as compared to vehicle-treated mice. Administration of PTH or rClec11a significantly increased the trabecular bone formation rate (Figure 6M) and the number of osteoblasts (Figure 6—figure supplement 2L) in dexamethasone-treated mice. As expected, dexamethasone treatment, or administration of PTH or rClec11a, did not significantly affect deoxypyridinoline levels (Figure 6N) or osteoclast numbers (Figure 6—figure supplement 2M). rClec11a thus prevented the loss of trabecular bone in dexamethasone-treated mice by promoting bone formation.
To test whether rClec11a could reverse bone loss after the onset of osteoporosis we ovariectomized two month-old wild-type mice and waited for four weeks before administering PTH or rClec11a daily for another four weeks. MicroCT analysis showed that trabecular and cortical bone volumes as well as trabecular number were significantly reduced in ovariectomized mice (Figure 7A–C, and Figure 7—figure supplement 1C). Trabecular spacing was significantly increased in ovariectomized mice (Figure 7E). Daily administration of PTH to ovariectomized mice increased trabecular bone volume (Figure 7B) and significantly reduced trabecular spacing relative to untreated ovariectomized mice (Figure 7E). PTH treatment also significantly increased cortical area (Figure 7—figure supplement 1C) and cortical thickness (Figure 7—figure supplement 1E). Daily administration of rClec11a to ovariectomized mice significantly increased trabecular bone volume (Figure 7B) and trabecular number (Figure 7C), while reducing trabecular spacing (Figure 7E) relative to untreated ovariectomized mice. rClec11a did not significantly affect cortical area (Figure 7—figure supplement 1C) or cortical thickness (Figure 7—figure supplement 1E) in ovariectomized mice. rClec11a can thus reverse trabecular bone loss after the onset of ovariectomy-induced osteoporosis.
To test whether human Clec11a also promotes osteogenesis, we constructed a HEK293 cell line that stably expressed human Clec11a with a C-terminal Flag tag, then affinity purified recombinant human Clec11a (rhClec11a) from the culture medium. Addition of rhClec11a to human bone marrow stromal cells cultured under osteogenic culture conditions significantly increased osteoblast differentiation based on alkaline phosphatase (Figure 7H and I) and alizarin red staining (Figure 7J and K).
To test whether rhClec11a promotes osteogenesis by human bone marrow stromal cells in vivo we subcutaneously transplanted a suspension of human bone marrow stromal cells, hydroxyapatite/tricalcium phosphate particles, and fibrin gel into immunocompromised NSG mice (Bianco et al., 2006) and administered daily subcutaneous injections of rhClec11a or vehicle for 4 or 8 weeks. rhClec11a significantly accelerated bone formation in the ossicles after four weeks and significantly increased bone formation in the ossicles after eight weeks (Figure 7L–O). rhClec11a thus promotes osteogenesis by human bone marrow stromal cells in vivo.
We have identified a new osteogenic factor, Clec11a, which maintains the adult skeleton by promoting the osteogenesis. Clec11a was necessary and sufficient to promote osteogenesis in culture and in vivo. Clec11a deficiency significantly reduced bone volume in both limb bones and vertebrae of adult mice (Figure 2). Clec11a was expressed by subsets of bone marrow stromal cells, osteoblasts, osteocytes, and hypertrophic chondrocytes, particularly in the metaphysis, but also in portions of cortical bone (Figure 1). In light of the unanticipated osteogenic activity of Clec11a, and its role in the maintenance of the adult skeleton, we propose to call this growth factor Osteolectin, a name that is more descriptive of both biological function and protein structure.
Clec11a/Osteolectin appears to promote bone formation by promoting the differentiation of mesenchymal progenitors into mature osteoblasts. Clec11a/Osteolectin deficient bone marrow stromal cells formed significantly fewer osteoblasts and mineralized bone matrix in culture (Figure 3A–D) with significantly lower expression of the mature osteoblast markers Ibsp and Dmp1 (Figure 3—figure supplement 1N). Addition of recombinant Clec11a/Osteolectin to cultures of wild-type bone marrow stromal cells significantly increased the formation of osteoblasts (Figure 5—figure supplement 1D) as well as Ibsp and Dmp1 expression (Figure 5—figure supplement 1G). Clec11a/Osteolectin deficient bone marrow stromal cells also formed less bone in the ossicles in vivo (Figure 3—figure supplement 1O–Q). Recombinant Clec11a/Osteolectin promoted bone formation in the ossicles in vivo (Figure 7L–O). In contrast to its effects on osteogenic differentiation, Clec11a/Osteolectin deficiency did not affect the frequency, proliferation, or survival of bone marrow mesenchymal progenitors in vivo (Figure 3—figure supplement 1B–M). Recombinant Clec11a/Osteolectin also did not have any effect on the frequency of CFU-F that formed colonies in culture (Figure 5—figure supplement 1A) or the number of cells per colony (Figure 5—figure supplement 1B). We conclude that Clec11a/Osteolectin promotes the osteogenic differentiation of mesenchymal progenitors but not their proliferation or survival.
Hypertrophic chondrocytes can also transdifferentiate into osteoblasts and osteocytes during endochondral ossification (Ono et al., 2014b; Yang et al., 2014; Zhou et al., 2014b). Thus, in addition to promoting the differentiation of mesenchymal progenitors into mature osteoblasts, Clec11a/Osteolectin might also promote the transdifferentiation of hypertrophic chondrocytes into osteoblasts. Lineage tracing studies will be required in future to test this.
Nobody has yet identified the receptor for Clec11a/Osteolectin, limiting our ability to study the signaling mechanisms by which it promotes osteogenesis. We do observe binding of flag-tagged Clec11a/Osteolectin to the surface of osteogenic cell lines (data not shown). We hypothesize that Clec11a/Osteolectin promotes the osteogenic differentiation of mesenchymal progenitors by binding to a signaling receptor on the surface of these cells. Identification of this receptor will require significant additional work beyond the scope of the current study.
Phylogenic analysis showed that Clec11a/Osteolectin is most closely related to Clec3b/Tetranectin. Tetranectin expression increases during mineralization by osteogenic progenitors in culture and overexpression of Tetranectin in PC12 cells increases the bone content of tumors formed by these cells (Wewer et al., 1994). Tetranectin deficient mice exhibit kyphosis as a result of asymmetric growth plate development in vertebrae (Iba et al., 2001); however, it is unknown whether Tetranectin is required for osteogenesis in vivo. Tetranectin is found in both cartilaginous fish and bony fish but Clec11a/Osteolectin is only found in bony fish and higher vertebrate species. This suggests that Clec11a/Osteolectin evolved in bony species to promote osteogenic differentiation and mineralization. Among mammals Clec11a/Osteolectin is highly conserved: human and mouse Clec11a/Osteolectin proteins are 85% identical and 90% similar. Consistent with this, recombinant human Clec11a/Osteolectin promoted osteogenesis by human bone marrow stromal cells in culture and in vivo (Figure 7H–O).
To generate Clec11a-/- mice, Cas9 mRNA and sgRNAs were transcribed using mMESSAGE mMACHINE T7 Ultra Kit and MEGAshortscript Kit (Ambion), purified by MEGAclear Kit (Ambion), and microinjected into C57BL/6 zygotes by the Transgenic Core Facility of the University of Texas Southwestern Medical Center (UTSW). Chimeric mice were genotyped by restriction fragment length polymorphism (RFLP) analysis and backcrossed onto a C57BL/Ka background to obtain germline transmission. Mutant mice were backcrossed onto a C57BL/Ka background for 3 to 6 generations prior to analysis. Wild-type C57BL/Ka mice were used for rClec11a injection, ovariectomy, and dexamethasone injection experiments. All procedures were approved by the UTSW Institutional Animal Care and Use Committee (Animal protocol number: 2016–101334-G). The cell lines used in this study included HEK293 and MC3T3-E1 (Subclone 4), which were obtained from ATCC and authenticated by STR profiling. They were shown to be free of mycoplasma contamination.
Antibodies used to analyze hematopoietic stem cells (HSCs) and multipotent hematopoietic progenitors (MPPs) included anti-CD150-PE-Cy5 (BioLegend, clone TC15-12F12.2, 1:200), anti-CD48-FITC (eBioscience, clone HM48-1, 1:200), anti-Sca-1-PEcy7 (eBioscience, E13-161.7, 1:200), anti-c-Kit-APC-eFluor780 (eBioscience, clone 2B8, 1:200) and the following antibodies against lineage markers: anti-Ter119-PE (eBioscience, clone TER-119, 1:200), anti-B220-PE (BioLegend, clone 6B2, 1:400), anti-Gr-1-PE (BioLegend, clone 8C5, 1:800), anti-CD2-PE (eBioscience, clone RM2-5, 1:200), anti-CD3-PE (BioLegend, clone 17A2, 1:200), anti-CD5-PE (BioLegend, clone 53–7.3, 1:400) and anti-CD8-PE (eBioscience, clone 53–6.7, 1:400). The following antibodies were used to identify restricted hematopoietic progenitors: anti-CD34-FITC (eBioscience, clone RAM34, 1:100); anti-CD16/32 Alexa Fluor 700 (eBioscience, clone 93, 1:200); anti-CD135-PEcy5 (eBioscience, clone A2F10, 1:100); anti-CD127-Biotin (BioLegend, clone A7R34, 1:200) + Streptavidin-PE-CF592 (BD Biosciences, 1:500); anti-cKit-APC-eFluor780 (eBioscience, clone 2B8, 1:200); anti-ScaI-PEcy7 (eBioscience, clone E13-161.7, 1:200) and lineage markers listed above. The following antibodies were used to identify differentiated cells: anti-CD71-FITC (BD Biosciences, clone C2, 1:200); anti-Ter119-APC (eBioscience, clone TER-119, 1:200); anti-CD3-PE (BioLegend, clone 17A2, 1:200); anti-B220-PEcy5 (eBioscience, clone RA3-6B2, 1:400); anti-Mac-1-APC-eFluor780 (eBioscience, M1/70, 1:200) and anti-Gr-1-PEcy7 (BioLegend, clone RB6-8C5, 1:400). Anti-CD45.2-FITC (BioLegend, clone 104, 1:200) and anti-CD45.1-APC-eFluor-78 (eBioscience, clone A20, 1:100) were used to distinguish donor from recipient cells in competitive reconstitution assays. The following antibodies were used to distinguish subpopulations of bone marrow stromal cells: anti-CD45-APC (eBioscience, clone 30-F11, 1:200), anti-Ter119-APC (eBioscience, clone TER-119, 1:200), anti-CD31-APC (Biolegend, clone MEC13.3, 1:200), anti-Tie2-APC (BioLegend, clone TEK4, 1:200), anti-Thy1.1-FITC (eBioscience, clone HIS51, 1:200), anti-Thy1.2-FITC (eBioscience, clone 30-H12, 1:200), anti-CD51-biotin (BioLegend, clone RMV-7, 1:100), anti-CD51-PE (BioLegend, clone RMV-7, 1:100), anti-Ly-51-PEcy7 (BioLegend, clone 6C3, 1:200), anti-CD200-PE (BioLegend, clone OX-90, 1:200), anti-CD105-Pacific Blue (BioLegend, clone MJ7/18), anti-LepR-biotin antibody (R and D systems, BAF497, 1:100) and anti-PDGFRα-biotin (eBioscience, clone APA5, 1:200). Cells were stained with antibodies in 200 µl of staining medium (HBSS + 2% fetal bovine serum) on ice for 1 hr, and then washed by adding 2 ml of staining buffer followed by centrifugation. Biotin-conjugated antibodies were incubated with streptavidin-PE or streptavidin-Brilliant Violet 421 (Biolegend, 1:500) for another 20 min (Biolegend, 1:500). Cells were resuspended in staining medium with 1 µg/ml DAPI (Invitrogen) and analyzed with a FACSCanto flow cytometer (BD Biosciences) or sorted using a FACSAria flow cytometer (BD Biosciences) with a 130 µm nozzle. To assess proliferation in vivo, mice were given a single intraperitoneal injection of BrdU (100 mg/kg body mass) and maintained on 0.5 mg/ml BrdU in the drinking water for 14 days. The frequency of BrdU+ SSCs was then analyzed by flow cytometry using the APC BrdU Flow Kit (BD Biosciences).
Enzymatic digestion of bone marrow cells and CFU-F cultures were performed as described previously (Suire et al., 2012). Briefly, intact marrow plugs were flushed from the long bones and subjected to two rounds of enzymatic digestion at 37°C for 15 min each. The digestion buffer contained 3 mg/ml type I collagenase (Worthington), 4 mg/ml dispase (Roche Diagnostic) and 1 U/ml DNase I (Sigma) in HBSS with calcium and magnesium. The cells were resuspended in staining medium (HBSS + 2% fetal bovine serum) with 2 mM EDTA to stop the digestion. To form CFU-F colonies, freshly dissociated single-cell suspensions were plated at clonal density in 6-well plates (5 × 105 cells/well) or 10 cm plates (5 × 106 cells/dish) with DMEM (Gibco) plus 20% fetal bovine serum (Sigma F2442, lot 14M255, selected to support CFU-F growth), 10 µM ROCK inhibitor (Y-27632, TOCRIS), and 1% penicillin/streptomycin (Invitrogen). Cultures were maintained at 37°C in gas-tight chambers (Billups-Rothenberg, Del Mar, CA) that were flushed daily for 30 s with 5% O2 and 5% CO2 (balance Nitrogen) to maintain a low oxygen environment that promoted survival and proliferation (Morrison et al., 2000). The CFU-F culture medium was changed on the second day after plating to wash out contaminating macrophages, then changed every 3–4 days after that. CFU-F colonies were counted eight days after plating by staining with 0.1% Toluidine blue in 4% formalin solution.
Osteogenic and adipogenic differentiation were assessed by replating primary CFU-F cells into 48-well plates (25,000 cells/cm2). On the second day of culture, the medium was replaced with adipogenic (four days) or osteogenic (seven days or 14 days) medium (StemPro MSC differentiation kits; Life Technologies). Equal numbers of cells from wild-type and Clec11a-/- cultures were replated so there was no difference in the density of cells of different genotypes. In some experiments, clonal differentiation potential was assessed by sorting 500 bone marrow LepR+CD105+CD45-Ter119-CD31- cells into each well of a 6-well plate to form CFU-F colonies at clonal density over an eight day period. Then the culture medium was replaced with osteogenic differentiation medium. Seven to 14 days later, the percentage of colonies that contained osteoblasts and the numbers of osteoblasts per colony were quantified by StemTAG Alkaline Phosphatase Staining and Activity Assay Kit (Cell Biolabs) and alizarin red staining (Sigma).
Chondrogenic potential was assessed by centrifuging 2 × 105 CFU-F cells to form cell pellets, which were then cultured in chondrogenic medium for 21 days (StemPro chondrogenesis differentiation kit; Life Technologies), changing the culture medium every 2–3 days. Chondrocyte formation within the cell pellets was assessed by cryosectioning and Toluidine blue staining (Robey et al., 2014). The osteogenic differentiation of human bone marrow stromal cells and MC3T3-E1 cells was tested using the StemPro osteogenesis differentiation kit (Life Technologies). Images were acquired using an Olympus IX81 microscope.
Femurs and lumbar vertebrae were dissected, fixed overnight in 4% paraformaldehyde and stored in 70% ethanol at 4°C. Femurs and lumbar vertebrae were scanned at an isotropic voxel size of 3.5 µm and 7 µm, respectively, with peak tube voltage of 55 kV and current of 0.145 mA (µCT 35; Scanco Medical AG, Bassersdorf, Switzerland). A three-dimensional Gaussian filter (σ = 0.8) with a limited, finite filter support of one was used to suppress noise in the images, and a threshold of 263–1000 was used to segment mineralized bone from air and soft tissues. Trabecular bone parameters were measured in the distal metaphysis of the femurs. The region of interest was selected from below the distal growth plate where the epiphyseal cap structure completely disappeared and continued for 100 slices toward the proximal end of the femur. Contours were drawn manually a few voxels away from the endocortical surface to define trabecular bones in the metaphysis (Bouxsein et al., 2010). Cortical bone parameters were measured by analyzing 100 slices in mid-diaphysis femurs. Vertebral bone parameters were measured by analyzing 200 slices in the middle of L3 lumbar vertebrae. The fracture callus was scanned at an isotropic voxel size of 6 µm with the same settings as described above. The region of interested was selected from 200 slices above the fracture site to 200 slices below the fracture site (400 slices in total), including the entire callus. A segmentation threshold of 263–500 was used to analyze the trabecular parameters in the fracture callus.
Two month-old adult recipient mice were irradiated with an XRAD 320 irradiator (Precision X-Ray Inc.), giving two doses of 550 rad, delivered at least 2 hr apart. C57BL/Ka-Thy-1.1 (CD45.2) donor mice and C57BL/Ka-Thy-1.2(CD45.1) recipient mice were used in transplant experiments. 300,000 donor whole bone marrow cells from Clec11a-/- or littermate control mice (CD45.2) were transplanted along with 300,000 recipient whole bone marrow cells (CD45.1) into lethally irradiated recipient mice (C57BL/Ka-Thy-1.1 x C57BL/Ka-Thy-1.2 (CD45.1/CD45.2) heterozygotes). Peripheral blood was obtained from the tail veins of recipient mice at 4 to 16 weeks after transplantation. Blood was subjected to ammonium-chloride lysis of the red blood cells and leukocytes were stained with antibodies against CD45.1, CD45.2, B220, Mac-1, CD3 and Gr-1 to assess hematopoietic chimerism by donor and recipient cells by flow cytometry.
Dissected bones were fixed in 4% paraformaldehyde overnight, decalcified in 10% EDTA for four days, and dehydrated in 30% sucrose for two days. Bones were sectioned (10 µm) using the CryoJane tape-transfer system (Leica). Sections were blocked in PBS with 10% horse serum for 30 min and then stained overnight at 4°C with goat IgG control (R and D Systems, 1:500), goat anti-Clec11a antibody (R and D systems, 1:500), rabbit anti-Aggrecan antibody (Chemicon, 1:500), rabbit anti-Perilipin antibody (Sigma, 1:2000) or goat anti-Osteopontin antibody (R and D, 1:500). Donkey anti-goat Alexa Fluor 488, Donkey anti-goat Alexa Fluor 647 and donkey anti-rabbit Alexia Fluor 555 were used as secondary antibodies (Invitrogen, 1:500). Slides were mounted with anti-fade prolong gold with DAPI (Invitrogen). Images were acquired using a Zeiss LSM780 confocal microscope or Olympus IX81 microscope.
On day 0 and day 7, mice were injected intraperitoneally with 10 mg/kg body mass calcein dissolved in calcein buffer (0.15 M NaCl plus 2% NaHCO3 in water) and sacrificed on day 9. The tibias were fixed overnight in 4% paraformaldehyde at 4°C, dehydrated in 30% sucrose for two days and sectioned without decalcification (7 µm sections). Mineral apposition and bone formation rates were determined as previously described (Egan et al., 2012). For the quantification of osteoblast number/bone surface and osteoclast number/bone surface, decalcified 10 µm femur sections were stained histochemically for alkaline phosphatase (Roche) or tartrate-resistant acid phosphatase (Sigma) activity. Growth plate chondrocytes were identified based on staining with Safranin O/fast green (American MasterTech) and quantified using Image J. Alizarin red/alcian blue double staining was performed as described previously (Ovchinnikov, 2009).
A stainless steel wire was inserted into the intramedullary canal of the femur through the knee after anesthesia, and a bone fracture was introduced in the femur mid-diaphysis by 3-point bending. Buprenorphine was injected every 12 hr up to 72 hr after the surgery.
Bone resorption rate was determined by measuring urinary levels of deoxypyridinoline (DPD) using a MicroVue DPD ELISA Kit (Quidel). The DPD values were normalized to urinary creatinine levels using the MicroVue Creatinine Assay Kit (Quidel).
Mouse Clec11a cDNA was cloned into pcDNA3 vector (Invitrogen) containing a C-terminal 1XFlag-tag, which was then transfected into HEK293 cells with Lipofectamine 2000 (Invitrogen) and subjected to stable cell line selection using 1 mg/ml G418 (Sigma). Stable clones with high Clec11a expression were cultured in DMEM plus 10% FBS (Sigma), and 1% penicillin/streptomycin (Invitrogen). Culture medium was collected every two days, centrifuged to eliminate cellular debris, and stored with 1 mM phenylmethylsulfonyl fluoride at 4°C to inhibit protease activity. One litter of culture medium was filtered through a 0.2 µm membrane to eliminate cellular debris (Nalgene) before being loaded onto a chromatography column containing 2 ml Anti-FLAG M2 Affinity Gel (Sigma), with a flow rate of 1 ml/min. The column was sequentially washed using 20 ml of high salt buffer (20 mM Tris-HCl, 300 mM KCl, 10% Glycerol, 0.2 mM EDTA) followed by 20 ml of low salt buffer (20 mM Tris-HCl, 150 mM KCl, 10% Glycerol, 0.2 mM EDTA) and finally 20 ml of PBS. The FLAG-tagged Clec11a was then eluted from the column using 10 ml 3X FLAG peptide (100 μg/ml) in PBS or protein storage buffer (50 mM HEPES, 150 mM NaCl and 10% glycerol, pH = 7.5). Eluted protein was concentrated using Amicon Ultra-15 Centrifugal Filter Units (Ultracel-10K, Millipore), then quantitated by SDS-PAGE and colloidal blue staining (Invitrogen) and stored at −80°C. The recombinant human Clec11a was generated and purified in the same way.
For ovariectomy-induced osteoporosis, 8 week-old virgin female mice were anesthetized using Isoflurane, shaved, and disinfected with Betadine. A dorsal midline incision was made and the periovarian fat pad was gently grasped to exteriorize the ovary. The fallopian tube was then clamped off and the ovary was removed by cutting above the clamped area. The uterine horn was returned into the abdomen and the same process was repeated on the other side. After surgery, buprenorphine was given for analgesia, and mice were closely monitored until they resumed full activity. Vehicle, 40 µg/kg PTH (1–34) or 50 µg/kg rClec11a were subcutaneously injected daily starting one day or four weeks after the surgery and continuing for 28 days then the mice were analyzed. For dexamethasone-induced osteoporosis, PBS or 20 mg/kg dexamethasone was injected peritoneally into eight week-old virgin female mice daily for 28 days. Vehicle, 40 µg/kg PTH (1–34) or 50 µg/kg rClec11a were subcutaneously injected at the same time.
Mouse and human bone marrow stromal cell ossicle formation in vivo was assessed as described previously (Bianco et al., 2006). Briefly, 2 × 106 mouse primary CFU-F cells were seeded into collagen sponges (Gelfoam, Pfizer), incubated at 37°C for 90 min, with or without 10 ng/ml rClec11a, and then transplanted subcutaneously into NSG mice. The ossicles formed by these cells were analyzed eight weeks after transplantation by cryosectioning and immunostaining with antibodies against perilipin and osteopontin. For human bone marrow stromal cells, 2 × 106 cells were incubated with 40 mg of hydroxyapatite (HA)/tricalcium phosphate (TCP) particles (65%/35%, Zimmer Dental, Warsaw IN), with or without 10 ng/ml rhClec11a, and rotated for 2 hr at 37°C. The cell/carrier slurry was centrifuged at 135xg for 5 min and embedded in a fibrin gel by adding 15 µl of human fibrinogen (3.2 mg/ml in sterile PBS) with 15 µl of human thrombin (25 U/ml in sterile 2% CaCl2 in PBS). The gels were left at room temperature for 10 min to clot, then transplanted subcutaneously into NSG mice. The ossicles formed by these cells were analyzed 4 or 8 weeks after transplantation by cryosectioning and H and E staining. Some of the mice were treated with daily subcutaneous injections of 50 µg/kg human recombinant Clec11a.
For quantitative reverse transcription PCR (qPCR), 6000 PDGFRα+CD45-Ter119-CD31- cells were flow cytometrically sorted from enzymatically dissociated bone marrow into Trizol (Invitrogen). RNA was extracted and reverse transcribed into cDNA using SuperScript III (Invitrogen). qPCR was performed using a Roche LightCycler 480. The primers used for qPCR analysis included Clec11a (NM_009131.3): 5’-AGG TCC TGG GAG GGA GTG-3’ and 5’-GGG CCT CCT GGA GAT TCT T-3’; Runx2 (NM_001146038.2): 5’- TTA CCT ACA CCC CGC CAG TC-3’ and 5’-TGC TGG TCT GGA AGG GTC C-3’; Sp7 (NM_130458.3): 5’- ATG GCG TCC TCT CTG CTT GA-3’ and 5’-GAA GGG TGG GTA GTC ATT TG-3’; Ibsp (NM_008318.3): 5’-AGT TAG CGG CAC TCC AAC TG-3’ and 5’-TCG CTT TCC TTC ACT TTT GG-3’; Dmp1 (NM_016779.2): 5’-TGG GAG CCA GAG AGG GTA G-3’ and 5’- TTG TGG TAT CTG GCA ACT GG-3’; Actb (NM_007393.5): 5’-GCT CTT TTC CAG CCT TCC TT-3’ (Forward) and 5’-CTT CTG CAT CCT GTC AGC AA-3’ (Reverse).
EdU was added into osteogenic differentiation medium at day 0 (10 μM final concentration) and maintained for the duration of the differentiation phase of the culture (8 days). The cultures were fixed by adding 1% paraformaldehyde on ice for 5 min then stained with alkaline phosphatase substrates (NBT/BCIP, Roche). Cells were then incubated with PBS supplemented with 3% FCS and 0.1% saponin for 5 min at room temperature, followed by Click-iT Plus reaction cocktail (Life Technologies) incubated for 30 min with 5 μM Alexa Fluor 555-azide. Cells were washed with PBS supplemented with 3% FCS and 0.1% saponin twice and quantified using an Olympus IX81 microscope. Caspase-3/7 enzymatic activity within individual cells growing adherently in culture plates was measured by adding CellEvent Caspase-3/7 Green Detection Reagent (a substrate for activated caspase-3/7, 2 μM final concentration; Life Technologies) to the differentiation medium at the end of the experiment and incubated for 30 min before fixation, alkaline phosphatase staining, and quantification.
Peripheral blood was collected from the tail vein using Microvette CB 300 K2E tubes (Sarstedt) and counted using a HEMAVET HV950 cell counter (Drew Scientific).
Hematopoietic colony formation was assessed by seeding 20,000 unfractionated mouse femur bone marrow cells into MethoCult M3334 or MethoCult M3234 supplemented with 10 ng/ml GM-CSF (STEMCELL Technologies). The cultures were incubated at 37°C for 10 days and then colonies were counted under the microscope.
Mouse plasma was diluted 1:1 using 2x PBS buffer and 100 μl of diluted serum was coated on each well of the 96-well ELISA plate (COSTAR 96-WELL EIA/RIA STRIPWELL PLATE) at 4°C for 16 hr. The plate was then washed three times with washing buffer (PBS with 0.1% Tween-20), blocked with 300 μl ELISA Blocker Blocking Buffer (Thermo, N502) for 2 hr at room temperature, and washed for three times with washing buffer. Anti-Clec11a antibody (1 μg/ml diluted in 100 μl of PBS buffer with 0.1% Tween-20 per well) was then added and incubated at room temperature for 2 hr, washed three times with washing buffer, followed by HRP-conjugated donkey anti-Goat IgG secondary antibody (0.8 μg/ml diluted in 100 μl of PBS buffer with 0.1% Tween-20 per well) incubation at room temperature for 1 hr. After washing for three times, 100 μl of SureBlue TMB Microwell Peroxidase Substrate was added to each well and incubated at room temperature in the dark for 15 min. Finally, 100 μl of the TMB stop solution was added into each well and the optical density was measured at 450 nm.
To assess biomechanical properties, the right femurs were harvested from mice, wrapped in saline-soaked gauze, and stored at –20°C. The femurs were rehydrated in PBS for at least 3 hr before testing, and then kept in a humidified chamber and preconditioned with 20 cycles of bending displacement (0.1 mm). Without immersion, the femurs were loaded to fracture with three-point bending (each holding point was 4 mm from the middle break point) under displacement control (3 mm/min) using a material testing system (Instron model # 5565, Norwood, MA).
To genotype Clec11a+/+, Clec11+/-, and Clec11a-/- mice the following primers were used: 5’-TTT GGG TGC TGG GAA GCC C-3’ and 5’-TTG CAC TGA GTC GCG GGT G-3’ (Clec11a+/+: 910 bp; Clec11+/- or Clec11a-/-: 538 bp). To distinguish between Clec11a+/-and Clec11a-/- mice, the following primers were used: 5’-GAG GAA GAG GAA ATC ACC ACA GC-3’ and 5’-TTG CAC TGA GTC GCG GGT G-3’ (Clec11a+/-: 482 bp; Clec11a-/-: no amplification product).
The statistical significance of differences between the two treatments was assessed using two-tailed Student's t tests. The statistical significance of differences among more than two groups was assessed using one-way ANOVAs with Tukey’s multiple comparison tests. The statistical significance of differences in long-term competitive reconstitution assays was assessed using two-way ANOVAs with Sidak’s multiple comparison tests. All data represent mean ± SD. *p<0.05, **p<0.01, ***p<0.001.
An RNA-seq protocol to identify mRNA expression changes in mouse diaphyseal bone: applications in mice with bone property altering Lrp5 mutationsJournal of Bone and Mineral Research 28:2081–2093.https://doi.org/10.1002/jbmr.1946
Molecular cloning of a new secreted sulfated mucin-like protein with a C-type lectin domain that is expressed in lymphoblastic cellsJournal of Biological Chemistry 273:1911–1916.https://doi.org/10.1074/jbc.273.4.1911
Guidelines for assessment of bone microstructure in rodents using micro-computed tomographyJournal of Bone and Mineral Research 25:1468–1486.https://doi.org/10.1002/jbmr.141
Stem cell growth factor: in situ hybridization analysis on the gene expression, molecular characterization and in vitro proliferative activity of a recombinant preparation on primitive hematopoietic progenitor cellsThe Hematology Journal 2:307–315.https://doi.org/10.1038/sj.thj.6200118
Mice with a targeted deletion of the tetranectin gene exhibit a spinal deformityMolecular and Cellular Biology 21:7817–7825.https://doi.org/10.1128/MCB.21.22.7817-7825.2001
Serum stem cell growth factor for monitoring hematopoietic recovery following stem cell transplantationBone Marrow Transplantation 32:391–398.https://doi.org/10.1038/sj.bmt.1704152
Collagen integrin receptors regulate early osteoblast differentiation induced by BMP-2Journal of Bone and Mineral Research 14:1075–1083.https://doi.org/10.1359/jbmr.1922.214.171.1245
Expression profile of osteoblast lineage at defined stages of differentiationJournal of Biological Chemistry 280:24618–24626.https://doi.org/10.1074/jbc.M413834200
Suppression of a novel hematopoietic mediator in children with severe malarial anemiaInfection and Immunity 77:3864–3871.https://doi.org/10.1128/IAI.00342-09
Parathyroid hormone analogues in the treatment of osteoporosisNature Reviews Endocrinology 7:647–656.https://doi.org/10.1038/nrendo.2011.108
Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signalingJournal of Biological Chemistry 280:19883–19887.https://doi.org/10.1074/jbc.M413274200
Romosozumab in postmenopausal women with low bone mineral densityNew England Journal of Medicine 370:412–420.https://doi.org/10.1056/NEJMoa1305224
Isolation and characterization of a cDNA for human mouse, and rat full-length stem cell growth factor, a new member of C-type lectin superfamilyBiochemical and Biophysical Research Communications 249:124–130.https://doi.org/10.1006/bbrc.1998.9073
Prospective identification, isolation, and systemic transplantation of multipotent mesenchymal stem cells in murine bone marrowThe Journal of Experimental Medicine 206:2483–2496.https://doi.org/10.1084/jem.20091046
The CCN family member Wisp3, mutant in progressive pseudorheumatoid dysplasia, modulates BMP and Wnt signalingJournal of Clinical Investigation 117:3075–3086.https://doi.org/10.1172/JCI32001
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosisNew England Journal of Medicine 344:1434–1441.https://doi.org/10.1056/NEJM200105103441904
A subset of chondrogenic cells provides early mesenchymal progenitors in growing bonesNature Cell Biology 16:1157–1167.https://doi.org/10.1038/ncb3067
Alcian blue/alizarin red staining of cartilage and bone in mouseCold Spring Harbor Protocols 2009:pdb.prot5170.https://doi.org/10.1101/pdb.prot5170
Bone marrow stromal cell assays: in vitro and in vivoMethods in Molecular Biology 1130:279–293.https://doi.org/10.1007/978-1-62703-989-5_21
Isolation and characterization of MC3T3-E1 preosteoblast subclones with distinct in vitro and in vivo differentiation/mineralization potentialJournal of Bone and Mineral Research 14:893–903.https://doi.org/10.1359/jbmr.19126.96.36.1993
A potential role for tetranectin in mineralization during osteogenesisThe Journal of Cell Biology 127:1767–1775.https://doi.org/10.1083/jcb.127.6.1767
Janet RossantReviewing Editor; University of Toronto, Canada
In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.
Thank you for submitting your article "Clec11a is an osteogenic factor that promotes the maintenance of the adult skeleton" for consideration by eLife. Your article has been reviewed by three peer reviewers, including Ophir D Klein (Reviewer #1), and the evaluation has been overseen by Janet Rossant as the Senior Editor and Reviewing Editor.
The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.
In this elegant and well-executed manuscript, the Morrison lab reports on their exciting discovery that a C-type lectin domain protein, Clec11a, promotes osteogenesis. Clec11a maintains the adult skeleton by promoting osteogenic differentiation of mesenchymal progenitors. The authors first determined that Clec11a is highly expressed in skeletal lineage cells by gene and protein expression analyses. They then employed the CRISPR-Cas9 system to generate a Clec11a knock out mouse to test if Clec11a is necessary for hematopoiesis and osteogenesis in vivo. They found that Clec11a deficiency led to weaker bones under conditions of normal homeostasis and also after fracture healing. The authors also tested whether administration of recombinant Clec11a is sufficient to prevent and reverse osteoporosis using micro-CT and histomorphometric analyses. The identification of Clec11a as a novel agonist of bone maintenance and fracture healing is of high interest and the data presented are very compelling. While the study does not define a clear molecular mechanism of action for Clec11a, multiple models of osteoporosis were used to demonstrate the efficacy of rClec11a, greatly strengthening the clinical relevance of the study.
Major revisions required:
Although there was overall support for the findings, there were concerns from the reviewers about the robustness of the data on the bone phenotypes, specifically about the rigor of the µCT and histomorphometry data. Reviewer 1 noted that there are standard protocols for assessing and reporting mouse bone microstructure (for example: Bouxsein et al., 2010 JBMR. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography). As presented here, the explanations for the exact location of the volume of interest and the method used to define trabecular and cortical bone regions are vague. If indeed the same number of slices were chosen for every timepoint, then it is likely that different anatomical regions within the growing femur were assessed. Details regarding image processing, including the algorithm used for image filtration and the approach used for calibration and image segmentation, should be added. Many of the units used by the authors to describe the various bone features differ from those recommended in standard protocols.
In addition, there was concern as to whether the sample size of mice analyzed was sufficient to support the conclusions in all cases. Typically, unless the effect size is substantial, labs need to study 8 to 10 mice/genotype/sex/treatment group for most bone parameters. Because you present "representative" images in this paper and no clear indication of the number or sex of animals included in each group, the reviewers were not convinced that all the reported in vivo effects represent true positive results. It will be important for you to address these concerns as far as is possible within the two month time frame, or focus your results on those experiments where you have a fully powered cohort.
Other concerns include explaining why mice with similar ages and genotypes have very different bone measures (e.g., BV/TV) in different figures and a need for a better description of the recombinant protein you produced and administered. Downstream experiments (beyond the scope of the present paper) could then determine if the effect on bone cells is direct or indirect, why fracture healing is delayed (osteoblast recruitment or transdifferentiation failure), and whether recombinant CLEC11A can be used as a therapeutic for common skeletal diseases such as fractures and osteoporosis.
Overall there was enthusiasm for the finding of a potentially novel osteogenic factor.https://doi.org/10.7554/eLife.18782.024
[…] Major revisions required:
Although there was overall support for the findings, there were concerns from the reviewers about the robustness of the data on the bone phenotypes, specifically about the rigor of the µCT and histomorphometry data. Reviewer 1 noted that there are standard protocols for assessing and reporting mouse bone microstructure (for example: Bouxsein et al., 2010 JBMR. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography). As presented here, the explanations for the exact location of the volume of interest and the method used to define trabecular and cortical bone regions are vague. If indeed the same number of slices were chosen for every timepoint, then it is likely that different anatomical regions within the growing femur were assessed. Details regarding image processing, including the algorithm used for image filtration and the approach used for calibration and image segmentation, should be added.
We believe we followed the standard protocols described by Bouxsein et al. (see details below). We have updated the text of the manuscript to clarify more precisely the locations of the volume measurements. We have included more details regarding the number of slices that were analyzed. Bone growth was very limited in the adult mice analyzed in our study so we do not believe that any of our results are confounded by changes in anatomical regions caused by bone growth. We have also updated the text to include more details regarding image processing and analysis.
For the femur trabecular bones, we started analyzing slices at the bottom of the distal growth plate, where the epiphyseal cap structure completely disappeared, and continued for 100 slices (3.5 μm/slice) toward the proximal end of the femur. Contours were drawn manually a few voxels away from the endocortical surface to define trabecular bones in the metaphysis, as suggested by the guideline (Figure 4D; JBMR 25:1468). For the femur cortical bones, 100 slices (3.5 μm/slice) in the mid-diaphysis were analyzed. The same anatomical regions were analyzed for all the samples throughout the manuscript. We have added details of microCT measurements and analyses as requested.
Many of the units used by the authors to describe the various bone features differ from those recommended in standard protocols.
In the original manuscript we used ratios instead of “%” for Bone volume/Total volume and Cortical area/Total area (i.e. 0.05 rather than 5%). We used “per mm” instead of “1/mm” (as recommended by Bouxsein et al.) for trabecular number and a few other measurements. We have now changed the units to be identical to those recommended by Bousein et al., though these changes have no effect on the data or the conclusions.
In addition, there was concern as to whether the sample size of mice analyzed was sufficient to support the conclusions in all cases. Typically, unless the effect size is substantial, labs need to study 8 to 10 mice/genotype/sex/treatment group for most bone parameters. Because you present "representative" images in this paper and no clear indication of the number or sex of animals included in each group, the reviewers were not convinced that all the reported in vivo effects represent true positive results. It will be important for you to address these concerns as far as is possible within the two month time frame, or focus your results on those experiments where you have a fully powered cohort.
There are multiple issues that bear clarification here:
1) In the original manuscript, we specified the number of mice per genotype and the number of independent experiments for each figure panel in the figure legends.
2) Although we did not have n=8 mice/sex/genotype in all experiments, all of our conclusions were based on statistically significant differences in which the statistical tests took into account variability within treatments as well as numbers of replicates. Many of the effects reported in our manuscript were large effects. For example, Clec11a deficiency has a large negative effect on bone volume in vivo (e.g. Figure 2D) and bone formation in culture (e.g. Figure 3D). Treatment with recombinant Clec11a has large positive effects on bone formation in culture (e.g. Figure 5B) and bone formation in vivo (e.g. Figure 5K). The fact that we consistently observed statistically significant differences in many different kinds of experiments, with both gain and loss of function assays that showed opposite results, in vitro and in vivo, makes it exceedingly unlikely that the effects could have been observed by chance.
3) The representative images in the figures were usually accompanied by bar graphs that showed all of the data from all of the experiments (with numbers of replicates and experiments in the figure legend) as well as statistical analysis.
Most of our experiments require more than 2 months to perform. However, we have performed new experiments and added more replicates for in vivo administration of rClec11a in wild-type mice (new Figure 5C–G), and for prevention of ovariectomy-induced osteoporosis by rClec11a (new Figure 6A–E). The new data were consistent with the old data: in vivo administration of rClec11a promotes bone formation in wild-type mice and in ovariectomized mice.
Other concerns include explaining why mice with similar ages and genotypes have very different bone measures (e.g., BV/TV) in different figures and a need for a better description of the recombinant protein you produced and administered.
Thank you for calling our attention to this. We have revised our presentation of these data to avoid confusion. We used both males and females of each genotype in Figure 2, whereas only females were used in Figures 5, 6 and 7 (e.g. ovariectomy studies could only be performed on females). Since adult male mice have significantly higher BV/TV values than female mice (see Figure 3B; JBMR 22:1197), it is not surprising that the 2 month-old BV/TV value in the control mice of Figure 2 (around 10%) is higher than in the rest of the manuscript (4-8%). Thus, the differences in BV/TV values in different figures mainly reflect expected biological differences, not experimental error. We have revised the manuscript to make clear the sexes that were used in each experiment. We have also added more detailed information on the recombinant protein and how it was purified.https://doi.org/10.7554/eLife.18782.025
- Sean J Morrison
- Sean J Morrison
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
SJM is a Howard Hughes Medical Institute (HHMI) Investigator, the Mary McDermott Cook Chair in Pediatric Genetics, the Kathryn and Gene Bishop Distinguished Chair in Pediatric Research, the director of the Hamon Laboratory for Stem Cells and Cancer and a Cancer Prevention and Research Institute of Texas Scholar. RY was supported by a Damon Runyon Cancer Research Foundation fellowship. We thank Nicolas Loof and the Moody Foundation Flow Cytometry Facility, Kristen Correll for mouse colony management, Christopher Chen for biomechanical analysis of bones, Malea Murphy for assistance with confocal imaging, Ying Liu, Jingya Wang and Jerry Q Feng at the Texas A and M University Baylor College of Dentistry for assistance with microCT experiments. This work was supported by the Cancer Prevention and Research Institute of Texas.
Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All procedures were approved by the UT Southwestern Medical Center Institutional Animal Care and Use Committee. Animal protocol number: 2016-101334-G
- Janet Rossant, University of Toronto, Canada
- Received: June 14, 2016
- Accepted: November 1, 2016
- Version of Record published: December 13, 2016 (version 1)
© 2016, Yue et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.